Quantcast
Last updated on April 21, 2014 at 5:21 EDT

Latest Clinical trial Stories

2014-03-28 12:26:46

Company Reports Phase III Trial Progress, Positive Regulatory and ASCO Decisions; BETHESDA, Md., March 28, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today refuted false and misleading claims by Adam Feuerstein in an article posted Thursday, March 27, after NW Bio's public presentation of significant positive news about all of the Company's programs....

2014-03-27 23:23:24

Developers at EyeKor, LLC, have introduced real-time reporting of key clinical trial performance metrics in EXCELSIOR™, the company’s clinical trial data management and image analysis software. New York, NY (PRWEB) March 27, 2014 EXCELSIOR™, an FDA 510(k)-cleared application, is a cloud-based platform specifically designed for ophthalmic clinical trial management. EXCELSIOR™ is focused on providing investigators, clinical trial sponsors, and clinical research organizations with...

2014-03-27 16:25:12

Successful IPO Positions Company for Multiple Independent Catalysts Over Next 5 Quarters LA JOLLA, Calif., March 27, 2014 /PRNewswire/ -- Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced its financial results for the fourth quarter and year ended December 31, 2013. "2014 has the potential to be a transformative year for Auspex as...

2014-03-27 08:34:50

JERUSALEM, March 27, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the first patient has been enrolled in its U.S. Phase 2a trial for its orally ingestible insulin capsule, ORMD-0801, in the treatment of type 1 diabetes (T1DM). "We are pleased to be initiating this U.S. clinical trial with ORMD-0801 in...

2014-03-26 23:27:31

Lead Investigator Discusses Findings With AJMC, Says Results Show Importance of Self-Testing Plainsboro, NJ (PRWEB) March 26, 2014 The American Journal of Managed Care (AJMC), on Monday published the results of the Self-Testing Analysis Based on Long-Term Experience (STABLE) study. It showed that self-testing significantly improves control of warfarin, as measured by time in therapeutic range (TTR). Results of the study, supported by Alere, were originally shared at the 2012 Scientific...

2014-03-26 12:29:07

iMedNet(TM) EDC Delivers an Innovative and Affordable eClinical Solution to Support Any Research Initiative MINNETONKA, Minn., March 26, 2014 /PRNewswire/ -- MedNet Solutions, a global life sciences technology company specializing in clinical study management systems, will once again be participating in the Partnerships in Clinical Trials conference. This year's event will be held March 30 - April 2 in Las Vegas, Nevada. Attendees are encouraged to visit MedNet's booth to see iMedNet EDC -...

2014-03-26 12:28:36

CINCINNATI, March 26, 2014 /PRNewswire-USNewswire/ -- Septic shock is a severe systemic infection and major cause of death for the old and young alike. Unfortunately, researchers say testing new drug regimens to stop the infection is confounded because clinical trials include patients who are either too sick to be saved by experimental therapies or not sick enough to warrant the treatments. http://photos.prnewswire.com/prnvar/20110406/MM79025LOGO In a study published in the April...

2014-03-26 08:30:18

-- Multi-Year Signings for Enterprise-wide Technology and Support -- NEWTOWN, Pa., March 26, 2014 /PRNewswire/ -- BioClinica®, Inc., a leading provider of specialized outsourced clinical trial services, today announced that it recently penned $30 million in multi-year contract renewals with two major pharmaceutical companies. Collectively these engagements encompass cloud-based technologies and professional services and training across BioClinica's full eClinical product suite:...

2014-03-26 08:29:24

SAN DIEGO, March 26, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported financial results for the fourth quarter and year ended December 31, 2013. "2013 was a year of great progress for Mast as we delivered on our operational goal of opening 40 clinical sites in the U.S. for EPIC, our pivotal Phase 3 study of MST-188 in sickle cell disease," said Brian M. Culley, Chief Executive Officer. "Already in 2014, we've achieved numerous operational and strategic...

2014-03-26 08:28:59

- Study will evaluate whether MST-188 improves the effectiveness of rt-PA SAN DIEGO, March 26, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) announced today that it has initiated a phase 2, clinical proof-of-concept study of MST-188 in combination with recombinant tissue plasminogen activator (rt-PA) in patients with acute lower limb ischemia. Acute limb ischemia (ALI), an acute complication of peripheral arterial disease, describes a sudden decrease in perfusion...